» Articles » PMID: 8665066

Life-threatening Effects of Discontinuing Inhaled Nitric Oxide in Severe Respiratory Failure

Overview
Specialty Critical Care
Date 1996 Jun 1
PMID 8665066
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

We present the effects of abrupt discontinuation of inhaled nitric oxide (NO) in four patients with severe hypoxemic respiratory failure. These patients ranged from 9 mo to 65 yr of age. In each patient, after the initiation of inhaled NO, a marginal, but immediate, beneficial effect on gas exchange and, when measured, a reduction in pulmonary artery pressures was noted. However, during attempts to discontinue inhaled NO, not only did these patients develop worsening oxygenation and recrudescence of pulmonary hypertension but, unexpectedly, these parameters were worse than the baseline values, leading to life-threatening hemodynamic instability. These effects reversed immediately after reinstitution of inhaled NO. The mechanism of this severe ¿rebound¿ in pulmonary hypertension after abrupt withdrawal of NO is unclear, but its existence emphasizes the need to avoid a substantial risk to these patients. Moreover, we believe that both unintentional and intentional termination of inhaled NO therapy may lead to life-threatening deterioration in gas exchange and circulatory hemodynamics that exceeds the initial therapeutic benefit.

Citing Articles

Stem cell therapy for pulmonary arterial hypertension: An update.

Sun Q, Sun Z J Heart Lung Transplant. 2022; 41(6):692-703.

PMID: 35341679 PMC: 9133091. DOI: 10.1016/j.healun.2022.02.020.


Droplet Size and Distribution of Nebulized 3% Sodium Chloride, Albuterol, and Epoprostenol by Phase Doppler Particle Analyzer.

McDermott K, Oakley J Curr Ther Res Clin Exp. 2021; 94:100623.

PMID: 34306263 PMC: 8296146. DOI: 10.1016/j.curtheres.2021.100623.


Compatibility and Safety Implications Associated with Interfacing Medical Devices in Neonatal Respiratory Care: A Case Example Using the Inhaled Nitric Oxide Delivery System.

DeWitt A, Acker J, Larkin T, Potenziano J, Schmidt J Med Devices (Auckl). 2021; 14:27-35.

PMID: 33628066 PMC: 7899041. DOI: 10.2147/MDER.S268477.


Rationale for Use of an FDA-Cleared Delivery System for Administration of Inhaled Nitric Oxide in Patients Undergoing Magnetic Resonance Imaging.

Salas M, Potenziano J, Acker J Med Devices (Auckl). 2021; 14:1-7.

PMID: 33442306 PMC: 7800703. DOI: 10.2147/MDER.S265099.


Nitric oxide and pulmonary arterial hypertension.

Chester A, Yacoub M, Moncada S Glob Cardiol Sci Pract. 2018; 2017(2):14.

PMID: 29644226 PMC: 5871404. DOI: 10.21542/gcsp.2017.14.